Physician profile
Monica Abrante
NPI 1295899359
$3,742.44
in general payments reported to CMS, 2019-2025
29 companies · $380 in 2025
The $380 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,614 · 2020: $262 · 2021: $220 · 2022: $628 · 2023: $374 · 2024: $265 · 2025: $380.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,019.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,018.67 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $614.19 | 2019-2025 | Breztri, Airsupra, Farxiga |
| Novo Nordisk INC | $536.89 | 2019-2025 | Rybelsus, Ozempic |
| Boehringer Ingelheim Pharmaceuticals, INC. | $404.10 | 2019-2025 | Jardiance |
| Philips North America LLC | $289.14 | 2019-2022 | |
| Astellas Pharma US INC | $272.25 | 2019-2025 | Veozah |
| Amgen INC. | $246.55 | 2019-2025 | Evenity, Prolia, Repatha |
| Glaxosmithkline, LLC. | $236.37 | 2019-2023 | Arexvy, Trelegy Ellipta |
| Ucb, INC. | $235.18 | 2019-2020 | |
| Sanofi-Aventis U.S. LLC | $200.36 | 2019-2020 | |
| Grifols USA, LLC | $82.99 | 2019-2022 | |
| Abbvie INC. | $82.38 | 2019 | |
| Lilly USA, LLC | $81.63 | 2019-2023 | Jardiance |
| Janssen Pharmaceuticals, INC | $59.70 | 2019 | |
| Novartis Pharmaceuticals Corporation | $54.00 | 2019-2020 | |
| Xeris Pharmaceuticals, INC. | $44.48 | 2021-2023 | Gvoke Hypopen |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $41.72 | 2023-2025 | Freestyle Libre 2, Freestyle Libre 3 |
| Allergan, INC. | $30.97 | 2019 | |
| Pfizer INC. | $29.78 | 2019-2020 | |
| Merck Sharp & Dohme LLC | $29.28 | 2019 | |
| Amarin Pharma, INC. | $28.10 | 2019-2020 | |
| Phathom Pharmaceuticals, INC. | $22.07 | 2024 | Voquezna |
| Shield Therapeutics INC | $21.19 | 2024 | |
| Corcept Therapeutics | $20.73 | 2023 | Korlym |
| Boston Scientific Corporation | $16.90 | 2023 | Solyx Sis System |
| Nestle Healthcare Nutrition INC. | $14.12 | 2023 | |
| Dexcom, INC. | $14.12 | 2023 | Dexcom G6 Transmitter |
| Seqirus USA INC | $11.74 | 2019 | |
| Zyla Life Sciences, INC. | $11.01 | 2019 | |
| Cequr Corporation | $10.50 | 2023 | Cequr Simplicity |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Monica Abrante listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.